 NeuroBo Pharmaceuticals, Inc. Nasdaq: NRBO, a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale in a registered direct offering of 750,000 shares of the Companys common stock, at a purchase price of 10.00 per share. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions. 